Literature DB >> 21239054

Secreted Gaussia luciferase as a sensitive reporter gene for in vivo and ex vivo studies of airway gene transfer.

Uta Griesenbach1, Catarina C Vicente, Megan J Roberts, Cuixiang Meng, Samia Soussi, Stefania Xenariou, Peter Tennant, Alison Baker, Eilidh Baker, Catherine Gordon, Christina Vrettou, Dominique McCormick, Rebecca Coles, Anne-Marie Green, Anna E Lawton, Stephanie G Sumner-Jones, Seng H Cheng, Ronald K Scheule, Stephen C Hyde, Deborah R Gill, David D Collie, Gerry McLachlan, Eric W F W Alton.   

Abstract

The cationic lipid GL67A is one of the more efficient non-viral gene transfer agents (GTAs) for the lungs, and is currently being evaluated in an extensive clinical trial programme for cystic fibrosis gene therapy. Despite conferring significant expression of vector-specific mRNA following transfection of differentiated human airway cells cultured on air liquid interfaces (ALI) cultures and nebulisation into sheep lung in vivo we were unable to detect robust levels of the standard reporter gene Firefly luciferase (FLuc). Recently a novel secreted luciferase isolated from Gaussia princeps (GLuc) has been described. Here, we show that (1) GLuc is a more sensitive reporter gene and offers significant advantages over the traditionally used FLuc in pre-clinical models for lung gene transfer that are difficult to transfect, (2) GL67A-mediated gene transfection leads to significant production of recombinant protein in these models, (3) promoter activity in ALI cultures mimics published in vivo data and these cultures may, therefore, be suitable to characterise promoter activity in a human ex vivo airway model and (4) detection of GLuc in large animal broncho-alveolar lavage fluid and serum facilitates assessment of duration of gene expression after gene transfer to the lungs. In summary, we have shown here that GLuc is a sensitive reporter gene and is particularly useful for monitoring gene transfer in difficult to transfect models of the airway and lung. This has allowed us to validate that GL67A, which is currently in clinical use, can generate significant amounts of recombinant protein in fully differentiated human air liquid interface cultures and the ovine lung in vivo.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21239054     DOI: 10.1016/j.biomaterials.2010.12.001

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  14 in total

1.  Enhanced Gaussia luciferase blood assay for monitoring of in vivo biological processes.

Authors:  M Sarah S Bovenberg; M Hannah Degeling; Bakhos A Tannous
Journal:  Anal Chem       Date:  2011-12-27       Impact factor: 6.986

2.  Secreted luciferase for in vivo evaluation of systemic protein delivery in mice.

Authors:  Salim S El-Amouri; Phuong Cao; Carol Miao; Dao Pan
Journal:  Mol Biotechnol       Date:  2013-01       Impact factor: 2.695

Review 3.  In vivo cell tracking with bioluminescence imaging.

Authors:  Jung Eun Kim; Senthilkumar Kalimuthu; Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2014-11-26

4.  An engineered biomarker system to monitor and modulate immune clearance of cell therapies.

Authors:  Amy Singleton; Danika Khong; Ling-Yee Chin; Shilpaa Mukundan; Matthew Li; Biju Parekkadan
Journal:  Cytotherapy       Date:  2017-09-13       Impact factor: 5.414

Review 5.  Secreted blood reporters: insights and applications.

Authors:  Bakhos A Tannous; Jian Teng
Journal:  Biotechnol Adv       Date:  2011-09-08       Impact factor: 14.227

6.  Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy.

Authors:  Panagiotis Mastorakos; Adriana L da Silva; Jane Chisholm; Eric Song; Won Kyu Choi; Michael P Boyle; Marcelo M Morales; Justin Hanes; Jung Soo Suk
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-29       Impact factor: 11.205

7.  Multiplex blood reporters for simultaneous monitoring of cellular processes.

Authors:  M Sarah S Bovenberg; M Hannah Degeling; Seyedali Hejazi; Romain J Amante; Marte van Keulen; Judith W M Jeuken; Sepideh Akbaripanahi; Carmen L A Vleggeert-Lankamp; Marie Tannous; Pieter Wesseling; Thomas Wurdinger; Bakhos A Tannous
Journal:  Anal Chem       Date:  2013-10-16       Impact factor: 6.986

8.  Exploiting ovine immunology to improve the relevance of biomedical models.

Authors:  Gary Entrican; Sean R Wattegedera; David J Griffiths
Journal:  Mol Immunol       Date:  2014-09-26       Impact factor: 4.407

9.  Evaluation of Gaussia luciferase and foot-and-mouth disease virus 2A translational interrupter chimeras as polycistronic reporters for transgene expression.

Authors:  Michael Puckette; Thomas Burrage; John G Neilan; Max Rasmussen
Journal:  BMC Biotechnol       Date:  2017-06-12       Impact factor: 2.563

10.  Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy.

Authors:  Uta Griesenbach; Makoto Inoue; Cuixiang Meng; Raymond Farley; Mario Chan; Nikki K Newman; Andrea Brum; Jun You; Angela Kerton; Amelia Shoemark; A Christopher Boyd; Jane C Davies; Tracy E Higgins; Deborah R Gill; Stephen C Hyde; J Alastair Innes; David J Porteous; Mamoru Hasegawa; Eric W F W Alton
Journal:  Am J Respir Crit Care Med       Date:  2012-09-06       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.